The Oncology & Precision Medicine Conference once again took place in Alderley Park over two days to encourage more in-depth discussion, with 132 delegates, exhibitors and speakers coming together to share ideas around these two areas of medicine.
The programme focused on Oncology on day one and Precision Medicine on day two, with a special conference edition of Biotech & Beers taking place on the evening of the first day.
Read the full event summary here
The Oncology & Precision Medicine 2024 Conference was sponsored by Appleyard Lees, Bruntwood SciTech, Innovaud and QIAGEN.
Agenda highlights:
Day 1 - Oncology
Keynote Speakers
Tim Maughan, Professor of Oncology, University of Liverpool
Caroline Phillips, CSO, Redx Pharma
Early Detection and Diagnosis
Chair: Rachel Mercer, Senior Associate, Appleyard Lees
Speakers
Phil Sloan, Chief Histopathologist, AMLo Biosciences
Lara Edwards, Programme Director, Health Data Research UK
Helen Fielder, Head of Technology, APIS Assay Technologis Ltd
Matt Owens, Lead Scientist, BioCaptiva
Treatments of the Future
Chair: Geoff Davison, CEO, Bionow
Speakers
Professor Klaus Pors, Professor of Chemical Biology, University of Bradford
Maria Paz Muñoz & Andrew Fielding, Senior Lecturer in Synthetic Chemistry, Lancaster University
Kate Brown, Translational Research Manager, Manchester Cancer Research Centre
Poster Spotlight Session
Speakers
Carrie Ambler, Biology Team Leader, LightOx
Phil Sloan, Chief Histopathologist , AMLo Biosciences
Sarah Farrow, Sales Manager, Atelerix
Paul Dickinson, Founder and CSO, SEDA PDS
Patient Perspective
Zoe Davison, Head of Research and Information, Bone Cancer Research Trust
Innovaud Session - Oncology Landscape and Global Expansion Opportunities in Western Switzerland
Frederic Reymond, Senior Investment Officer – Life Sciences & FoodTech, Innovaud
"Hot Topics" Panel Discussion
Chair: Paul Dickinson, Founder & CSO, SEDA Pharmaceutical Development Services
Speakers
Anu Sethi, Director, Business Development, Sterling Pharma
Catherine Bladen, Chief Operating Officer, Absolute Antibody
Dominic James, Exec in Residence,Cumulus Oncology & CSO, Nodus Oncology
Sam Butterworth, Professor of Medicinal Chemistry, University of Manchester Rare Disease Centre
Day 2 – Precision Medicine
Keynote Speakers
Munitta Muthana, Professor of Immuno-Oncology, University of Sheffield
Paul Fisher, Head of Policy, Programmes and Compliance, BIVDA
State of the Nation Panel
Chair: Alan Boyd, President and CEO, Boyds
Speakers
Sarah Brockbank, Strategy Leader - Complex Meds, Medicines Discovery Catapult
Lizzie WIlls, Senior Partner, GK Strategy
Mark Iles, Associate Professor, University of Leeds
Munitta Muthana, Professor of Immuno-Oncology, University of Sheffield
Precision Medicine in Chronic Diseases
Chair: Jane Theaker, Director, SpinXperts
Speakers
Steve Gardner, CEO & Co-Founder, Precision Life
Rowan Flynn, Principal Scientist, RoslinCT
Chris Ward, Chief Scientific Officer, Stratastem
Precision Medicine in Rare Diseases
Chair: Stella James, Executive Director, Business Development
Speakers
Linda Popplewell, Professor of Molecular Therapies, Teesside University
Daniel Gibson, Head of Collaborations, Cell & Gene Therapy Catapult
Siddharth Banka, Professor of Genomic Medicine and Rare Diseases, University of Manchester Rare Disease Centre
QIAGEN Session: The making of the QIAcuityDx - from RUO to IVD
Speakers
Dr Emma Newsham. Senior Product Development Lead, QIAGEN Manchester Longitudinal monitoring of cfDNA in NSCLC
Dr Kate Brown (Manchester, Translational Research Manager, Cancer Research Centre
